Open access
Open access
Powered by Google Translator Translator

Oncology (all articles)

RCT | Superior PFS with avelumab vs. chemotherapy in second-line treatment for mCRC with microsatellite instability

11 Aug, 2023 | 15:25h | UTC

Avelumab vs Standard Second-Line Chemotherapy in Patients With Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial – JAMA Oncology

See also: Visual Abstract

Commentary: Avelumab Outperforms Standard Second-Line Therapy in dMMR/MSI Metastatic CRC – Cancer Therapy Advisor

 


RCT – 2ry analysis | Aerobic exercise intervention shows potential to reduce chemotherapy-induced peripheral neuropathy

11 Aug, 2023 | 15:17h | UTC

Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial – JAMA Network Open

See also: Visual Abstract

Commentary: Aerobic Exercise Cuts Chemotherapy-Induced Peripheral Neuropathy Symptoms – HealthDay

 

Commentary on Twitter

 


Phase 2 RCT | Adding stereotactic body radiotherapy to immune checkpoint inhibitors fails to improve outcomes in solid tumor patients

9 Aug, 2023 | 15:28h | UTC

Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

See also: Visual Abstract

Commentary: Addition of SBRT to Immunotherapy in Advanced Solid Tumors – The ASCO Post

 


Cohort Study | Moderate to heavy drinking linked to increased risk of early-onset colorectal cancer

9 Aug, 2023 | 15:27h | UTC

Sex and Tumor-Site Differences in the Association of Alcohol Intake With the Risk of Early-Onset Colorectal Cancer – Journal of Clinical Oncology

Commentary: Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer – The ASCO Post

 

Commentary on Twitter

 


Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey

8 Aug, 2023 | 13:22h | UTC

Determination of “borderline resectable” pancreatic cancer – A global assessment of 30 shades of grey – HPB

 

Commentary on Twitter

 


Systematic Review | Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer

8 Aug, 2023 | 13:11h | UTC

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer – Cochrane Library

 


Cohort Study | Potential negative survival impact of PPI and palbociclib co-administration in breast cancer patients

8 Aug, 2023 | 13:07h | UTC

Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer – JAMA Network Open

Commentary: Proton Pump Inhibitors May Compromise Efficacy of Palbociclib in Patients With Breast Cancer – Cancer Therapy Advisor

 


RCT | Upfront radiosurgery reduces tumor volume vs. a wait-and-scan approach in small- to medium-sized vestibular schwannoma

7 Aug, 2023 | 14:40h | UTC

Upfront Radiosurgery vs a Wait-and-Scan Approach for Small- or Medium-Sized Vestibular Schwannoma: The V-REX Randomized Clinical Trial – JAMA (free for a limited period)

See also: Visual Abstract

 

Commentary on Twitter

 


RCT | Zolbetuximab plus CAPOX as potential first-line treatment for CLDN18.2+, HER2- advanced gastric adenocarcinoma

7 Aug, 2023 | 14:38h | UTC

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial – Nature Medicine

 

Commentary on Twitter

 


RCT | Mammography screening with AI reduces workload by 44.3% without loss in detection efficacy

4 Aug, 2023 | 12:13h | UTC

Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study – The Lancet Oncology (link to abstract – $ for full-text)

News Release: First randomized trial finds AI-supported mammography screening is safe and almost halves radiologist workload – Lancet

Commentaries:

Large Mammography Study Shows Significant Benefits with AI-Aided Screening – Diagnostic Imaging

Expert reaction to interim safety analysis of randomised trial on AI-supported mammography screening – Science Media Centre

 


Study | Removal of thymus in adults linked to increased death, cancer incidence

4 Aug, 2023 | 12:09h | UTC

Health Consequences of Thymus Removal in Adults – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries:

Doctors have long considered the thymus expendable. But could removing it be fatal? – Science

The thymus withers away after puberty. But it may be important for adults – Science News

Thymus gland critical for adult health, study finds – News Medical

 

Commentary on Twitter

 


NICE Updated Guideline | Diagnosis and management of lung cancer

4 Aug, 2023 | 12:05h | UTC

Lung cancer: diagnosis and management – National Institute for Health and Care Excellence

 


ASCO Guideline Update | Management of Stage III Non–Small-Cell Lung Cancer

4 Aug, 2023 | 12:03h | UTC

Management of Stage III Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology

Commentary: Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management – ASCO Daily News

 


ACP Guidance | Asymptomatic CRC screening advised from age 50 with fecal occult blood test every 2 years or colonoscopy every 10 years

3 Aug, 2023 | 13:48h | UTC

Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians – Annals of Internal Medicine

News Release: ACP issues updated guidance for colorectal cancer screening of asymptomatic adults – American College of Physicians

Commentary: Start screening for colorectal cancer at age 50 years, ACP suggests – ACP Internist

Summary for Patients: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults – Annals of Internal Medicine

 


Systematic Review | Interstitial lung disease incidence at 11.7% in metastatic breast cancer patients using trastuzumab deruxtecan

3 Aug, 2023 | 13:36h | UTC

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis – ESMO Open

 


M-A | Significant QOL and mental health improvements in caregivers via targeted interventions

3 Aug, 2023 | 13:28h | UTC

Interventions to improve outcomes for caregivers of patients with advanced cancer: a meta-analysis – JNCI: Journal of the National Cancer Institute

 


RCT | No significant recurrence-free survival improvement with everolimus post-renal carcinoma surgery

3 Aug, 2023 | 13:17h | UTC

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 


RCT | Early oral antibiotic switch in low-risk neutropenic sepsis shows mixed results

3 Aug, 2023 | 13:15h | UTC

Early switch to oral antibiotic therapy in patients with low risk neutropenic sepsis (EASI-SWITCH): A randomized non-inferiority trial – Clinical Microbiology and Infection

 


Review | Atypical hyperplasia of the breast: Clinical cases and management strategies

3 Aug, 2023 | 13:07h | UTC

Atypical hyperplasia of the breast: Clinical cases and management strategies – Cleveland Clinic Journal of Medicine

 


RCT | Lazertinib offers 20.6-month of median PFS in EGFR-mutated NSCLC vs 9.7 months with gefitinib

2 Aug, 2023 | 13:55h | UTC

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 – Journal of Clinical Medicine

 


RCT | Camrelizumab-rivoceranib outperforms sorafenib as first-line therapy for unresectable HCC

2 Aug, 2023 | 13:53h | UTC

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study – The Lancet (link to abstract – $ for full-text)

 

Commentary on Twitter

 


M-A | High-volume disease, T stage 4 show largest docetaxel benefit in prostate cancer

2 Aug, 2023 | 13:51h | UTC

Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials – The Lancet Oncology

Commentaries:

Meta-analysis of the Addition of Docetaxel to ADT in Metastatic Hormone-Sensitive Prostate Cancer – The ASCO Post

Disease Volume and T Stage Affect Docetaxel/ADT Efficacy in Prostate Cancer – Cancer Network

 

Commentary on Twitter

 


European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma

1 Aug, 2023 | 14:24h | UTC

Part 1: Diagnostics and prevention – European Journal of Cancer

Part 2: Treatment – European Journal of Cancer

 


Nonrandomized Controlled Trial | Long-term survival of 80% in selected colorectal cancer patients post liver transplant

1 Aug, 2023 | 14:20h | UTC

Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial – JAMA Surgery (link to abstract – $ for full-text)

 

Commentary on Twitter

 


RCT | Niraparib after first-line platinum-based chemotherapy extends PFS vs. placebo in newly diagnosed advanced ovarian cancer

31 Jul, 2023 | 13:58h | UTC

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial – JAMA Oncology

See also: Visual Abstract

Commentary: Niraparib Maintenance in Newly Diagnosed Advanced Ovarian Cancer – The ASCO Post

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.